Bexarotene: a promising anticancer agent

被引：60

作者：

Qu, Liyan ^{[1
]}

Tang, Xiuwen ^{[1
]}

机构：

[1] Zhejiang Univ, Sch Med, Dept Biochem & Genet, Hangzhou 310058, Zhejiang, Peoples R China

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2010年 / 65卷 / 02期

关键词：

Bexarotene; Cell cycle; Apoptosis; Differentiation; Multidrug resistance; X-RECEPTOR AGONIST; CELL LUNG-CANCER; OVERCOMES MULTIDRUG-RESISTANCE; CHEMOTHERAPY-NAIVE PATIENTS; NF-KAPPA-B; ORAL BEXAROTENE; PHASE-II; TARGRETIN PREVENTS; MYCOSIS-FUNGOIDES; MYELOID-LEUKEMIA;

D O I：

10.1007/s00280-009-1140-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Retinoids are biologically active derivatives of vitamin A, which play essential roles in embryonic or adult cell behavior modulating cell proliferation, differentiation and apoptosis. The biologic effects of retinoids are mediated by two distinct families of intracellular receptors: retinoid acid receptors (RARs)-alpha, -beta and -gamma and retinoid X receptors (RXR)-alpha, -beta and -gamma. Bexarotene is a selective RXR agonist, which exerts its effects in blocking cell cycle progression, inducing apoptosis and differentiation, preventing multidrug resistance, and inhibiting angiogenesis and metastasis, making it a promising chemopreventive agent against cancer.

引用

页码：201 / 205

页数：5

共 65 条

[41] Randomized phase III trial comparing bexarotene (L106949)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I [J].

Ramlau, Rodryg ;

Zatloukal, Petr ;

Jassem, Jacek ;

Schwarzenberger, Paul ;

Orlov, Sergei V. ;

Gottfried, Maya ;

Pereira, Jose Rodrigues ;

Temperley, Guillermo ;

Negro-Vilar, Rosa ;

Rahal, Samia ;

Zhang, Joseph K. ;

Negro-Vilar, Andres ;

Dziewanowska, Zofia E. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) :1886-1892

[42] A phase I study of bexarotene and rosiglitazone in patients with refractory cancers [J].

Read, William L. ;

Baggstrom, Maria Q. ;

Fracasso, Paula M. ;

Govindan, Ramaswamy .

CHEMOTHERAPY, 2008, 54 (03) :236-241

[43] Clinging to life: cell to matrix adhesion and cell survival [J].

Reddig, PJ ;

Juliano, RL .

CANCER AND METASTASIS REVIEWS, 2005, 24 (03) :425-439

[44] Emerging role of rexinoids in non-small cell lung cancer: Focus on bexarotene [J].

Rigas, JR ;

Dragnev, KH .

ONCOLOGIST, 2005, 10 (01) :22-33

[45]

Rizvi N, 2001, Clin Lung Cancer, V2, P210, DOI 10.3816/CLC.2001.n.005

[46] Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate [J].

Steinhoff, Matthias ;

Beyer, Marc ;

Roewert-Huber, Joachim ;

Lukowsky, Ansgar ;

Assaf, Chalid ;

Sterry, Wolfram .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (05) :S88-S91

[47] Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma [J].

Straus, David J. ;

Duvic, Madeleine ;

Kuzel, Timothy ;

Horwitz, Steven ;

Demierre, Marie-France ;

Myskowski, Patricia ;

Steckel, Stevim .

CANCER, 2007, 109 (09) :1799-1803

[48]

TALPUR R, 2009, J AM ACAD DERMA 0812

[49]

Tamm I, 1998, CANCER RES, V58, P5315

[50] CELLULAR-LOCALIZATION OF THE MULTIDRUG-RESISTANCE GENE-PRODUCT P-GLYCOPROTEIN IN NORMAL HUMAN-TISSUES [J].

THIEBAUT, F ;

TSURUO, T ;

HAMADA, H ;

GOTTESMAN, MM ;

PASTAN, I ;

WILLINGHAM, MC .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (21) :7735-7738

← 1 2 3 4 5 6 7 →